In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer

Involvement of DNA-PKcs in the IL-6 and IL-12 Response to CpG-ODN Is Mediated by Its Interaction with TRAF6 in Dendritic Cells

(2013) Chi Ma et al.   PLoS One

Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27

(2010) Mingli Xu et al.   Clinical & Developmental Immunology

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells

(2010) N N Kreis et al.   ONCOGENE

Long-Term Protection Against Human Papillomavirus E7-Positive Tumor by a Single Vaccination of Adeno-Associated Virus Vectors Encoding a Fusion Protein of Inactivated E7 of Human Papillomavirus 16/18 and Heat Shock Protein 70

(2009) Liqiao Zhou et al.   HUMAN GENE THERAPY

Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity

(2008) Sun-Je Woo et al.   CANCER SCIENCE

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

(2008) M. J.P. Welters et al.   CLINICAL CANCER RESEARCH